Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:36:32.250Z.
Consensus retrieved: 2026-10-06T10:35:12.997Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:36:32.250Z.
Quote observation: 2026-10-06T14:35:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5ada2dbbe5eb5c089a63970618dab48cacb437ed23bc9544d0e31521aeb048a1
Forward PE Ratio (N/A) = Dated Quote Price ($5.76) / Consensus Forward EPS ($-0.34)
FORWARD PE RATIO
N/A
Cytek Biosciences, Inc.
Market Cap
$744.51M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Cytek Biosciences, Inc. (CTKB) | $744.51M | N/A |
| Candel Therapeutics, Inc. (CADL)vs › | $743.69M | N/A |
| Design Therapeutics, Inc. (DSGN)vs › | $748.55M | N/A |
| Attovia Therapeutics, Inc. (ATTO)vs › | $755.39M | N/A |
| Mesa Laboratories, Inc. (MLAB)vs › | $765.35M | N/A |
| Avalo Therapeutics, Inc. (AVTX)vs › | $722.78M | N/A |
| Geron Corporation (GERN)vs › | $769.83M | N/A |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $770.68M | N/A |
| Achieve Life Sciences, Inc. (ACHV)vs › | $712.45M | N/A |
| Collegium Pharmaceutical, Inc. (COLL)vs › | $703.70M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $5.76, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.34 | $-0.35 – $-0.34 | 1 | n/m |
| 2027-12-31 | $-0.25 | $-0.26 – $-0.25 | 1 | n/m |
| 2028-12-31 | $-0.21 | $-0.29 – $-0.14 | 2 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
